Draupnir Bio expands research operations with new facility at INCUBA research park

Draupnir Bio expands research operations with new facility at INCUBA research park

August 2021

2 min

Copenhagen, Denmark, 12 August 2021 – Draupnir Bio (“Draupnir”), a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, today announces an expansion of its operations with the opening of a new research facility at INCUBA Skejby, a leading life sciences development cluster in Aarhus, Denmark.

INCUBA is a state-of-the-art science park and professional community, consistingof around 200 startups, scaleups and established companies and more than 1,500 employees, researchers, entrepreneurs, investors, and specialists. INCUBA Skejby, the healthcare arm of the park, sits within Business Park Skejby, one of Denmark's most knowledge-intensive areas within the health sector. The dynamic environment of the emerging biotech cluster that includes Aarhus University Hospital provides many opportunities for business development and collaboration.

The new site provides Draupnir with the required facilities to support the Company’s preclinical research organisation and the advancement of its innovative pipeline of small molecule therapeutics, as well as expanding capacity to enable future growth. Draupnir is headquartered in Copenhagen.

Andrew Hotchkiss, Chief Executive Officer of Draupnir Bio, said: “Our new research facility at INCUBASkejby gives us everything we need to continue to grow as a company in our own dedicated incubator space. INCUBA Skejby is an established park which offers a network of experts within the health sector, being home to many other leading life science companies who share a collaborative spirit. We’re looking forward to this next chapter in our company’s development as we push towards transforming the treatment of heart disease.”


For more information, please contact:

Draupnir Bio

Andrew Hotchkiss, Chief Executive Officer


Consilium Strategic Communications

David Daley, Genevieve Wilson, Kumail Waljee

Phone: +44 (0)20 3709 5700

Email: draupnirbio@consilium-comms.com

Notes to editors

About Draupnir Bio

Draupnir Bio is a Danish biotechnology company developing small molecule therapeutics to transform the treatment of heart disease, based on proprietary structural insights and the biology of Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9), a protein that enables a key step in the control of plasma low density lipoprotein cholesterol (LDLC) levels. The company was founded in 2017 as a spin-out from Aarhus University, Denmark, and the Max-Planck Institute, Germany. Backed by a syndicate of leading European investors, in 2019 Draupnir Bio completed a Series A funding round, raising €30 million Euros with participation from Gilde Healthcare Partners, Inkef Capital, Novo Seeds and High-Tech Gründerfonds. The Company is headquartered in Copenhagen, with research operations centered in Aarhus, Denmark.

© Draupnir Bio